---
title: "Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295680444.md"
description: "Definium Therapeutics announced positive Phase 3 trial results for DT120 in treating generalized anxiety disorder. The Voyage trial met its primary endpoint, showing significant and rapid symptom improvement over placebo with a favorable safety profile. This marks the second successful Phase 3 readout for DT120. Following the announcement, Definium's stock rose 5.72% to $43.25."
datetime: "2026-08-12T14:23:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295680444.md)
  - [en](https://longbridge.com/en/news/295680444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295680444.md)
---

# Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'

Late-stage clinical biopharmaceutical firm **Definium Therapeutics, Inc.** (NASDAQ:DFTX) has announced highly encouraging topline data from its Voyage trial.

The Phase 3 study evaluated the efficacy of DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults suffering from generalized anxiety disorder (GAD).

The Voyage trial successfully met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement over placebo.

The update marks the second successful Phase 3 readout for DT120 ODT, arriving shortly after the company reported positive Emerge trial data for major depressive disorder in June.

**Read Also: Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints**

## Rapid And Sustained Symptom Improvement

When measuring the change in the Hamilton Anxiety Rating Scale (HAM-A) total score at the 12-week mark, participants treated with DT120 ODT 100 µg saw a Least Squares (LS) mean reduction of 11.6 points.

In contrast, the placebo group experienced a 6.2-point drop.

This resulted in an LS mean difference of 5.4 points in favor of the therapeutic, establishing a standardized effect size of 0.81.

Notably, patients experienced rapid efficacy, with noticeable symptom changes starting as early as the second day and continuing throughout the evaluation period.

“The unprecedented efficacy demonstrated in Voyage should raise the bar for what patients and clinicians expect from GAD treatments…,” said **Rob Barrow**, CEO of Definium Therapeutics.

“Importantly, the consistent, large effect size we’ve now observed across three studies underscores the potential of DT120 to transform psychiatry and usher in a new era of mental health care.”

## Safety And Tolerability Profile

The therapeutic demonstrated a favorable safety profile and was generally well tolerated by participants. Any treatment-emergent adverse events were categorized as mild to moderate, temporary, and mostly limited to the day of administration.

Researchers observed no new safety concerns, including a complete absence of suicidal behaviors or ideation.

On the day patients received their dose, medical professionals monitored them using a structured end-of-session checklist.

Participants met the required criteria in an average of 6.4 hours, with a median time of 6.1 hours. The vast majority, 92%, successfully met the checklist criteria by the eight-hour mark.

**DFTX Stock Price Activity**: Definium Therapeutics shares were up 5.72% at $43.25 on Wednesday, according to Benzinga Pro data.

_Image via Shutterstock_

**Read Also: Elon Musk Could Score $824 Billion Payday in Tesla-SpaceX Merger—Ross Gerber Says ‘Fantastical Abundance!’**

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md)
- [SPCX.US](https://longbridge.com/en/quote/SPCX.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)
- [Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo](https://longbridge.com/en/news/295787298.md)
- [Definium says LSD-based pill reduces anxiety in late-stage study](https://longbridge.com/en/news/295653550.md)
- [Will Strong Phase 3 Depression Data and Q2 Review Webcast Change Definium Therapeutics' (DFTX) Narrative](https://longbridge.com/en/news/294588855.md)
- [This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/296231890.md)